• 1
    Mizutani G, Nakanishi Y, Watanabe N, et al. Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem. 2012;45:167176.
  • 2
    Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:32763281.
    Direct Link:
  • 3
    di Bartolomeo M, Bajetta E, Buzzoni R. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by Italian Trials in Medical Oncology Group. Cancer. 1996;77:402408.
  • 4
    Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707716.
  • 5
    Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell, Oxford; 2009.
  • 6
    Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. World Health Organization Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010.
  • 7
    Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20:11721182.
  • 8
    Corleto VD, Falconi M, Panzuto F, et al. Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology. 2009;89:223230.
  • 9
    Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:7779.
  • 10
    Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003;1616:184.
  • 11
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742753.
  • 12
    Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995;92:15801584.
  • 13
    Janson ET. Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary. 2006;9:249256.
  • 14
    Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B, Pavel M. Impact of octreotide LAR on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2012;95:157176.
  • 15
    Schmid HA, Lambertini C, van Vugt HH, et al. Monoclonal antibodies against the human somatostatin receptor subtypes 1–5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology. 2012;95:232247.
  • 16
    Hamilton NA, Liu TC, Cavatiao A, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012;152:107113.
  • 17
    Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234243.
  • 18
    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501513.
  • 19
    Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514523.
  • 20
    Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51:10331038.
  • 21
    Terashima T, Morizane C, Hiraoka N, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology. 2012;96:324332.
  • 22
    Wildemberg LE, Vieira Neto L, Costa DF, et al. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry. J Endocrinol Invest. 2012;35:580584.